Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

Carl Zeiss Meditec to showcase new clinical and productivity tools at AAO annual meeting

Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.

24 Oct 2011

Embryonic stem cell therapy patents knocked back in Europe

The European Union's highest court ruled Tuesday that scientists cannot patent stem cell techniques that use human embryos for research, a decision some scientists said could threaten major medical advances if it prevents biotech companies from turning a profit.

20 Oct 2011

RetroSense, WSU sign license agreement for channelrhodopsin-based approaches

RetroSense Therapeutics, LLC, a Michigan-based company, announced that it has executed its exclusive, worldwide option and signed a license agreement for novel gene-therapy approaches for treating blindness developed at Wayne State University's School of Medicine.

19 Oct 2011

Omron's home monitors can help control high blood pressure

According to the American Diabetes Association (ADA), recent estimates project that as many as one in three American adults will have diabetes in 2050. The ADA has named the month of November American Diabetes Month to help educate people on simple ways they can help manage, control and even prevent early signs of the disease - such as high blood pressure.

15 Oct 2011

Potential vaccine against trachoma

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

10 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

Cedars-Sinai to co-sponsor World Stem Cell Summit

Six leaders in stem cell research from the Cedars-Sinai Regenerative Medicine Institute will be key presenters at the world's largest interdisciplinary stem cell meeting Oct. 3-5 in Pasadena, Calif.

30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

Scientists report discovery of potential new drug for epidemic keratoconjunctivitis

Scientists are reporting discovery of a potential new drug for epidemic keratoconjunctivitis (EKC) - sometimes called "pink eye" - a highly infectious eye disease that may occur in 15 million to 20 million people annually in the United States alone. Their report describing an innovative new "molecular wipe" that sweeps up viruses responsible for EKC appears in ACS's Journal of Medicinal Chemistry.

29 Sep 2011

Two computerized tests increase ability to detect remaining vision in patients with RP

Two new computerized tests increase the ability to measure remaining vision in patients with retinitis pigmentosa (RP) and other blinding diseases, reports a study in the October issue of Optometry Vision Science, official journal of the American Academy of Optometry.

27 Sep 2011

JDRF, iCo Therapeutics collaborate for iCo-007 Phase 2 trial in DME

iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.

26 Sep 2011

Embryonic stem cell therapy for incurable Stargardt eye disease

...

26 Sep 2011

AGTC receives FFB grant to evaluate gene therapy treatment for X-linked Retinoschisis

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1.5 million from the Foundation Fighting Blindness to fund a pre-clinical trial evaluating the safety and efficacy of a gene therapy treatment for X-linked Retinoschisis (XLRS), a genetic eye disease affecting over 35,000 patients in the US and Europe.

22 Sep 2011

ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt's Macular Dystrophy using retinal pigment epithelium (RPE) derived from human embryonic stem cells.

22 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Amakem receives €18m in Series A round of funding

Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

6 Sep 2011

Discovery in rare disease may shed light on common causes of blindness

In a rare eye disease, the retina degenerates because light-receiving cells fail to regenerate, research led by a student at Case Western Reserve University School of Medicine shows.

2 Sep 2011

Insight into molecular basis of Enhanced S-Cone Syndrome

A new research report published in The FASEB Journal will help ophthalmologists and scientists better understand a rare genetic disease that causes increased susceptibility to blue light, night blindness, and decreased vision called Enhanced S-Cone Syndrome or Goldman-Favre Syndrome.

2 Sep 2011

New genetic cause of retinitis pigmentosa

Combining the expertise of several different labs, University of Iowa researchers have found a new genetic cause of the blinding eye disease retinitis pigmentosa (RP) and, in the process, discovered an entirely new version of the message that codes for the affected protein.

10 Aug 2011

Hydrogen sulfide protects blood vessels from diabetes complications

Hydrogen sulfide is a foul-smelling gas with an odor resembling that of rotten eggs. Sometimes called "swamp gas," this toxic substance is generally associated with decaying vegetation, sewers and noxious industrial emissions. And - as odd as it may seem - it also plays a critical role in protecting blood vessels from the complications of diabetes, according to a new study from the University of Texas Medical Branch at Galveston.

3 Aug 2011